
Novo Nordisk’s ultra-long-acting basal insulin Tresiba (insulin degludec) has been shown to be superior to French rival Sanofi’s Lantus (insulin glargine) in reducing severe cases of low blood sugar. This is according to a press release from the Danish diabetes group.
Novo has released the headline results from its major cardiovascular risk trial Devote, which the US FDA asked it to conduct after the agency initially rejected approval of Tresiba back in 2013.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app